Oncology
PSMA+ mCRPC
Expert Roundtables Podcast: Redefining Prostate Cancer in the Era of Advanced Diagnostics
Advanced diagnostic tools, such as prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans, have revolutionized the diagnosis of prostate cancer. However, they also pose challenges for clinicians making treatment decisions in patients with low-risk disease. In this podcast, prostate cancer experts Neeraj Agarwal, MD, FASCO, Peter R. Carroll, MD, MPH, and William K. Oh, MD, discuss the importance of redefining prostate cancer in the era of advanced diagnostics.
Armstrong AJ, Morris MJ, Abida W, et al; PCWG4 Writing Group. Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4. J Clin Oncol. 2026;44(13):1249-1265. doi:10.1200/JCO-25-02834
Carlsson SV, Carroll PR, Hamdy FC. Reevaluating the definition of clinically significant prostate cancer as Grade Groups 2 to 5: an imperative for improved risk stratification. J Urol. 2025;213(2):238-241. doi:10.1097/JU.0000000000004253
ClinicalTrials.gov. A study of an intermittent ADT approach with apalutamide monotherapy in participants with mCSPC (LIBERTAS). Updated September 25, 2026. Accessed October 26, 2026. https://clinicaltrials.gov/study/NCT05884398
ClinicalTrials.gov. Intermittent androgen deprivation therapy in the era of AR pathway inhibitors. Updated September 19, 2025. Accessed October 26, 2026. https://clinicaltrials.gov/study/NCT05974774
ClinicalTrials.gov. Safety and efficacy study of enzalutamide plus leuprolide in patients with nonmetastatic prostate cancer (EMBARK). Updated October 26, 2026. Accessed October 26, 2026. https://clinicaltrials.gov/study/NCT02319837
Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol. 2010;28(23):e408. doi:10.1200/JCO.2010.28.7664
Fizazi K, Clarke NW, De Santis M, et al; CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37(1):53-68. doi:10.1016/j.annonc.2025.10.004
Oh WK, Agarwal N, Bryce A, et al. What’s in a name? Why words matter in advanced prostate cancer. Eur Urol. 2025;87(2):101-103. doi:10.1016/j.eururo.2024.10.017
Pezaro CJ, Omlin A, Mastris K, et al; ANZUP Consumer Advisory Panel. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer. Ann Oncol. 2017;28(8):1692-1694. doi:10.1093/annonc/mdx312
